Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition ...

Pfizer is one of the largest pharmaceutical companies on the planet. It has a proven track record of finding, developing, and commercializing new drugs. The recent price advance is worth paying ...

Pfizer appears cheap with a near 7% yield, but capital allocation constraints undermine its investment case. Nearly all of PFE's free cash flow is consumed by dividends, leaving little for buybacks, ...

Pfizer’s revenue soared to record heights a few years ago thanks to its coronavirus products, but growth has since slowed. The company is counting on new products, and a focus on oncology, to drive ...